Clinical Trial

Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 30, 2025 (before its estimated June 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Heart failure with reduced ejection fraction (HFrEF) is a significant cause of morbidity and mortality. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated efficacy in improving renal outcomes in patients with HFrEF. Pharmacogenetics, the study of how genetic variations influence drug response, could elucidate inter-individual variability in treatment outcomes. This study aims to assess the impact of specific genetic variants on renal outcomes in HFrEF patients treated with SGLT2 inhibitors.
Trial Details
NCT Number NCT06901609
Lead Sponsor Ain Shams University
Collaborators: National Heart Institute, Egypt, Misr International University, Princess Nourah Bint Abdulrahman University
Conditions Heart Failure - NYHA II - IV, Cardiac Fibrosis, Cardiac Remodeling
Enrollment 200 participants
Start Date 2023-11-22
Primary Completion 2025-06-01 (estimated)
Study Completion 2025-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-30